Oxaliplatin Injection shortage
Oxaliplatin Injection is currently listed in shortage by the FDA. The FDA lists 6 affected products. This page was last refreshed from FDA data on Sep 25, 2026.
Multiple manufacturers are permanently stopping production of oxaliplatin injection. Other makers not reporting a shortage still list oxaliplatin 5 mg/mL as available.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Oxaliplatin Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Jun 29, 2026Currently in shortage6 of 6 products affected.
-
Jun 29, 2026More presentations reported2 more products added to the shortage.
-
Feb 25, 2026FDA refreshed this shortage record2 products updated.
-
Feb 25, 2026More presentations reported2 more products added to the shortage.
-
Oct 20, 2025First reported to the FDA2 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Fresenius Kabi USA, LLC 📞 847-550-2300 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Oxaliplatin, Injection, 5 mg/mL (NDC 63323-750-20) | — | — | A business decision was made to discontinue manufacture of the drug. | — |
| To Be Discontinued | Oxaliplatin, Injection, 5 mg/mL (NDC 63323-750-10) | — | — | A business decision was made to discontinue manufacture of the drug. | — |
Manufacturer: Jiangsu Hengrui Pharmaceuticals Co., Ltd. 📞 Sagent Pharmaceuticals: 866-625-1618 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Oxaliplatin, Injection, 5 mg/1 mL (NDC 25021-233-20) | — | — | Marketed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Oxaliplatin, Injection, 5 mg/1 mL (NDC 25021-233-10) | — | — | Marketed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug | — |
Manufacturer: Sandoz Inc. 📞 800-525-8747 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Oxaliplatin, Injection, 5 mg/1 mL (NDC 0781-3315-70) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Oxaliplatin, Injection, 5 mg/1 mL (NDC 0781-3317-80) | — | — | Discontinuation of the manufacture of the drug | — |
These rows are manufacturer reports to the FDA for Oxaliplatin Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Oxaliplatin Injection? options further down this page.
Why is Oxaliplatin Injection in shortage?
A few manufacturers have reported to the FDA that they are permanently stopping production of their versions of Oxaliplatin Injection 5 mg/mL. Specifically, Fresenius Kabi USA made a business decision to discontinue making their product, and both Jiangsu Hengrui Pharmaceuticals (marketed under the Sagent Pharmaceuticals name) and Sandoz Inc. have also decided to stop manufacturing their versions. All of the affected products are the 5 mg/mL concentration.
No specific reason beyond a business decision was shared publicly by these manufacturers — no factory problems, no safety issues, nothing like that was mentioned in their reports to the FDA. It's also worth noting that this report only covers these three manufacturers and their specific products. No dates were provided for when remaining supply will run out.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Oxaliplatin Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Oxaliplatin Injection?
Oxaliplatin Injection is currently on the FDA shortage list, and I want to walk you through what that means for you.
This record covers both listed strengths — 5 mg/mL and 5 mg/1 mL — and neither has an available source from the manufacturers on this report. The status is listed as "to be discontinued," which means these particular makers (Fresenius Kabi, Sagent/Jiangsu Hengrui, and Sandoz) have made a business decision to stop manufacturing their versions. This may be a permanent change for those products rather than a temporary supply gap.
Importantly, this report reflects only the manufacturers who filed it. Because oxaliplatin is given as part of cancer care, decisions about your treatment belong with your oncology team, and there are other companies that make this same medicine.
- Do not stop or change your treatment on your own — this is managed by your care team.
- Because your strength is being discontinued, ask your prescriber or pharmacist what comes next; they can plan the right path for you.
- The same medicine (oxaliplatin 5 mg/mL injection) is still listed from other makers, including Sandoz, Baxter, Accord, Hospira, and others — your pharmacy may be able to source one, though it may not be in local stock.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is national, manufacturer-reported data and may not match your local supply.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Oxaliplatin Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Oxaliplatin Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Oxaliplatin | OXALIPLATIN 5 mg/mL | Injection, Solution · Intravenous | Sandoz Inc | 00781-9315-70 |
| Oxaliplatin | OXALIPLATIN 5 mg/mL | Injection, Solution, Concentrate · Intravenous | Winthrop U.S, a business of sanofi-aventis U.S. LLC | 00955-1731-10 |
| Oxaliplatin | OXALIPLATIN 5 mg/mL | Injection, Solution, Concentrate · Intravenous | Accord Healthcare Inc. | 16729-0332-03 |
| Oxaliplatin | OXALIPLATIN 5 mg/mL | Injection, Solution · Intravenous | Baxter Healthcare Corporation | 43066-0014-01 |
| Oxaliplatin | OXALIPLATIN 5 mg/mL | Injection, Solution · Intravenous | Eugia US LLC | 55150-0331-01 |
| Oxaliplatin | OXALIPLATIN 5 mg/mL | Injection, Solution · Intravenous | Apotex Corp. | 60505-6132-06 |
| Oxaliplatin | OXALIPLATIN 5 mg/mL | Injection, Solution, Concentrate · Intravenous | Hospira, Inc. | 61703-0363-18 |
| Oxaliplatin | OXALIPLATIN 5 mg/mL | Injection, Solution · Intravenous | Mylan Institutional LLC | 67457-0442-20 |
| Oxaliplatin | OXALIPLATIN 5 mg/mL | Injection, Solution · Intravenous | BluePoint Laboratories | 68001-0468-36 |
| Oxaliplatin | OXALIPLATIN 5 mg/mL | Injection, Solution · Intravenous | Meitheal Pharmaceuticals Inc. | 71288-0101-10 |
| Oxaliplatin | OXALIPLATIN 5 mg/mL | Injection, Solution · Intravenous | FOSUN PHARMA USA INC. | 72266-0161-01 |
| Oxaliplatin | OXALIPLATIN 5 mg/mL | Injection, Solution · Intravenous | NorthStar Rx LLC | 72603-0101-01 |
Therapeutic equivalents & pricing 30 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Oxaliplatin 5 mg/mL | Winthrop | 1 vial | — | — | Discontinued |
| Oxaliplatin 5 mg/mL | Winthrop | 1 vial | — | — | Discontinued |
| oxaliplatin 5 mg/mL | Accord | 1 vial | — | AP | FDA listed |
| Oxaliplatin 5 mg/mL | Gland | 1 vial | — | AP | FDA listed |
| Oxaliplatin 5 mg/mL | Gland | 1 vial | — | AP | FDA listed |
| Oxaliplatin 5 mg/mL | Gland | 1 vial | — | AP | FDA listed |
| Oxaliplatin 5 mg/mL | Sandoz | 1 vial | — | AP | FDA listed |
| Oxaliplatin 5 mg/mL | Apotex | 1 vial | — | — | FDA listed |
| Oxaliplatin 5 mg/mL | FOSUN | 1 vial | — | AP | FDA listed |
| Oxaliplatin 5 mg/mL | Sandoz | 1 vial | — | AP | FDA listed |
| Oxaliplatin 5 mg/mL | Sandoz | 1 vial | — | AP | FDA listed |
| Oxaliplatin 5 mg/mL | Meitheal | 1 vial | — | AP | FDA listed |
| Oxaliplatin 5 mg/mL | NorthStar | 1 vial | — | AP | FDA listed |
| Oxaliplatin 5 mg/mL | Northstar | 1 vial | — | AP | FDA listed |
| Oxaliplatin 5 mg/mL | Sandoz | 1 vial | — | AP | FDA listed |
| Oxaliplatin 5 mg/mL | Eugia | 1 vial | — | — | FDA listed |
| Oxaliplatin 5 mg/mL | Eugia | 1 vial | — | — | FDA listed |
| Oxaliplatin 5 mg/mL | Meitheal | 1 vial | — | AP | FDA listed |
| oxaliplatin 5 mg/mL | Sagent | 1 vial | — | — | FDA listed |
| Oxaliplatin 5 mg/mL | Meitheal | 1 vial | — | AP | FDA listed |
| Oxaliplatin 5 mg/mL | FOSUN | 1 vial | — | AP | FDA listed |
| Oxaliplatin 5 mg/mL | Baxter | 1 vial | — | AP | FDA listed |
| Oxaliplatin 5 mg/mL | Meitheal | 1 vial | — | AP | FDA listed |
| Oxaliplatin 5 mg/mL | NorthStar | 1 vial | — | AP | FDA listed |
| oxaliplatin 5 mg/mL | Shandong | 10 vials | — | AP | FDA listed |
| Oxaliplatin 5 mg/mL | Mylan | 1 vial | — | AP | FDA listed |
| Oxaliplatin 5 mg/mL | BluePoint | 1 vial | — | — | FDA listed |
| Oxaliplatin 5 mg/mL | Northstar | 1 vial | — | AP | FDA listed |
| Oxaliplatin 5 mg/mL | Apotex | 1 vial | — | — | FDA listed |
| Oxaliplatin 5 mg/mL | Hospira, | 1 vial | — | AP | Discontinued |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Oxaliplatin Injection — that fall in the same broad treatment class (antineoplastic - alkylating agents) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other oncology shortages
Oxaliplatin Injection shortage FAQs
Is Oxaliplatin Injection in shortage?
Which products are affected?
When will Oxaliplatin Injection be available again?
Can I still get Oxaliplatin somewhere?
What should I do if I take Oxaliplatin Injection?
Still have a question about the Oxaliplatin Injection shortage?
Ask a pharmacist about this shortage →View Oxaliplatin Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.